^
    Back
    Association details:
    Biomarker:PTEN mutation
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    NPJ Breast Cancer
    Title:

    Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

    Published date:
    04/16/2021
    Excerpt:
    In this clinical study, which selectively targeted the aggressive PTEN-mutant ER+ MBC, capivasertib plus fulvestrant was tolerable and clinically active.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1038/s41523-021-00251-7
    Trial ID:
    NCT01226316